YEM Search

搜索结果

CACNA1S

靶点ID:TCMBANKGE009951

靶点别名:CACNL1A3; CCHL1A3; Cav1.1; HOKPP; HOKPP1; MHS5; TTPP1; hypoPP

靶点描述:calcium voltage-gated channel subunit alpha1 S

染色体:1

染色体位置:1q32.1

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:1397

OMIM_Link:114208

Ensembl_Link:ENSG00000081248

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN009329	magnesium sulfate		MgSO4	120.37 g/mol	[O-]S(=O)(=O)[O-].[Mg+2]
TCMBANKIN018942	ACon1_001856	(1R,3aR,4S,6aR)-1,4-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan; MEGxp0_001363	C24H30O8	446.5 g/mol	COC1=CC(=CC(=C1OC)OC)C2C3COC(C3CO2)C4=CC(=C(C(=C4)OC)OC)OC
TCMBANKIN034837	corycavine	7,16-Dimethyl-6,8,9,16-tetrahydrobis(1,3)benzodioxolo(4,5-c:5',6'-g)azecin-15(7H)-one; BG01348418; NSC123402; BRD-A25851298-001-01-3; NSC 123402; C-54667; WOLWLEQYUFDNTA-UHFFFAOYSA-N; 521-87-9; NCI60_000225; AC1Q6P90; Ambap521-85-7; 7,16-Dimethyl-6,8,9,16-tetrahydrobis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-15(7H)-one; Bis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-13(5H)-one, 4,6,7,14-tetrahydro-5,14-dimethyl-, (R)-; Corycavamine, (+/-)-; 2,15-DIMETHYL-7,9,19,21-TETRAOXA-15-AZAPENTACYCLO[15.7.0.0?,(1)(2).0?,(1)?.0(1)?,(2)(2)]TETRACOSA-1(24),4,6(10),11,17,22-HEXAEN-3-ONE; AKOS000277068; ACon1_002262; ACM521857; NSC-123402; CORYCAVINE; Dibenzo[c,g]azecin-13-one, perhydro-6,14-dimethyl-3,4:10,11-bis(methylenedioxy)-; AC1L5J6U; 7,16-Dimethyl-6,8,9,16-tetrahydrodi[1,3]benzodioxolo[4,5-c:5,6-g]azecin-15(7H)-one #	C21H21NO5	367.4	CC1C2=C(CN(CCC3=CC4=C(C=C3C1=O)OCO4)C)C5=C(C=C2)OCO5
TCMBANKIN036942	denudanolide D		C23H28O6	400.465	c1([C@]2([H])[C@@]([H])(C([H])([H])[H])[C@]3(OC([H])([H])[H])OC(=O)[C@@]2([H])C(=C([H])[H])C(C([H])([H])C([H])=C([H])[H])=C3[H])c([H])c(OC([H])([H])[H])c(OC([H])([H])[H])c(OC([H])([H])[H])c1[H]
TCMBANKIN048253	yangambin	yangambin; C10894; ZINC04098936; (1S,3aR,4S,6aR)-1,4-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan; 13060-14-5	C24H30O8	446	O1[C@]([H])(c2c([H])c(OC([H])([H])[H])c(OC([H])([H])[H])c(OC([H])([H])[H])c2[H])[C@@]([H])(C([H])([H])O[C@]3([H])c4c([H])c(OC([H])([H])[H])c(OC([H])([H])[H])c(OC([H])([H])[H])c4[H])[C@]3([H])C1([H])[H ]
TCMBANKIN061320	cryptopine		C21H23NO5	369.41	CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC
TCMBANKIN061354	Fumarine	C05189; TNP00339; 7-methyl-2,3:9,10-bis[methylenebis(oxy)]-7,13a-secoberbin-13a-one; ST036759; Bis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; Bis(1,3)benzodioxolo(4,5-c:5',6'-g)azecin-13(5H)-one, 4,6,7,14-tetrahydro-5-methyl-; HSCI1_000268; EINECS 204-999-6; AIDS-040935; Corydinine; 4,6,7,14-Tetrahydro-5-methyl-bis(1,3)benzodioxolo(4,5-c-5',6'-g)azecin-13(5H)-one; Oprea1_722246; NCGC00142402-01; Biflorine; Macleyine; 130-86-9; NCGC00017389-01; 7-methyl-6,8,9,16-tetrahydrobis[1,3]benzodioxolo[4,5-c:5',6'-g]azecin-15(7H)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:9,10-bis(methylenedioxy)-; Alk-3; 6164-47-2 (HCL); Oprea1_718853; AIDS040935; 7-Methyl-2,3:9,10-bis(methylenedioxy)-7,13a-secoberbin-13a-one; HSDB 3527; CHEBI:16415; AI3-62909; ACon1_001550; DTXSID00178935; Bis(1,3)benzodioxolo(5,6-c:5',6'-g)azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; Bis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6H)-one,5,7,8,15-tetrahydro-6-methyl-; AC1L4H3I; CHEMBL486179; 14-METHYL-7,9,20,22-TETRAOXA-14-AZAPENTACYCLO[15.7.0.0?,(1)(2).0?,(1)?.0(1)?,(2)(3)]TETRACOSA-1(24),4,6(10),11,17,19(23)-HEXAEN-2-ONE; CTK4F3162; MCULE-2865552640; BDBM50377937; 24240-05-9; AC1Q6P91; NCGC00385257-01_C20H19NO5_1,3-Benzodioxolo[5,6-c][1,3]benzodioxolo[5,6-g]azecin-14(6H)-one, 5,7,8,15-tetrahydro-6-methyl-; C20H19NO5; protopine ; Pseudoprotopine; MolPort-028-610-216; 6-methyl-5,7,8,15-tetrahydrobis[1,3]benzodioxolo[5,6-c:5',6'-g]azecin-14(6h)-one; 7,13a-Secoberbin-13a-one, 7-methyl-2,3:10,11-bis(methylenedioxy)-; ZINC31502517; protopine	C20H19NO5	353.37	CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C5=C(C=C4)OCO5)OCO3
TCMBANKIN061617	eugenol 4-Allyl-2-methoxyphenol		C10H12O2		COC1=C(C=CC(=C1)CC=C)O
TCMBANKIN061784	lirioresinol b dimethyl ether	1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-, (1S,3aR,4S,6aR)-; C24H30O8; ( )-O,O-Dimethyllirioresinol B; 1H,3H-Furo(3,4-c)furan, 3aalpha,4,6,6aalpha-tetrahydro-1alpha,4alpha-bis(3,4,5-trimethoxyphenyl)-; ( )-Yangabin; Yangabin; 1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4,5)-trimethoxyphenyl)-, 1alpha,3aalpha,4alpha,6aalpha)-; CCRIS 8944; Lirioresinol B dimethyl ether; O,O-Dimethyllirioresinol B; lirioresinol b dimethyl-ether; Lirioresinol B, dimethyl-; LS-70759; (1S-(1alpha,3aalpha,4alpha,6aalpha))-isomer of epiyangambin; Lirioresinol B, O,O-dimethyl-; (- )-lirioresinol B; ACon1_001856; (1R,3aR,4S,6aR)-1,4-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan; MEGxp0_001363; CTK4E6827; DTXSID10175733; SCHEMBL17385618; AC1L4ZYE; (1r,3ar,4r,6ar)-1,4-bis(3,4,5-trimethoxyphenyl)tetrahydro-1h,3h-furo[3,4-c]furan; 1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-,(1R,3aR,4R,6aR)-; Diayangambin; (+)-Diayangambin; AC1Q70YI; (3R,3aR,6R,6aR)-3,6-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan; Tetrahydro-1,4-bis(3,4,5-trimethoxyphenyl)-(1R)-1alpha,3abeta,4alpha,6abeta-1H,3H-furo(3,4-c)furan; 21453-68-9; ZINC31477287; yangambin; C10894; ZINC04098936; (1S,3aR,4S,6aR)-1,4-bis(3,4,5-trimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan; 13060-14-5; Yangambin; diayangambin	C24H30O8	446.5 g/mol	COC1=CC(=CC(=C1OC)OC)C2C3COC(C3CO2)C4=CC(=C(C(=C4)OC)OC)OC

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000883	Nutritional and Metabolic Diseases	Abnormality of metabolism/homeostasis	Finding	phenotype
TCMBANKDI001818	Endocrine System Diseases	Abnormality of the endocrine system	Disease or Syndrome	disease
TCMBANKDI003494	Pathological Conditions, Signs and Symptoms	Abnormality of the respiratory system	Finding	phenotype
TCMBANKDI003906	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the musculature	Finding	phenotype
TCMBANKDI004384	Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases	-	Disease or Syndrome	disease
TCMBANKDI006835	-	Abnormality of head or neck	Congenital Abnormality	disease
TCMBANKDI007343	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	-	Finding	phenotype
TCMBANKDI008314	Eye Diseases	-	Disease or Syndrome	disease
TCMBANKDI009394	Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases	-	Finding	phenotype
TCMBANKDI009912	Pathological Conditions, Signs and Symptoms	Abnormality of metabolism/homeostasis	Sign or Symptom	phenotype
TCMBANKDI012172	Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases	Abnormality of the cardiovascular system	Finding	phenotype
TCMBANKDI013913	Nervous System Diseases	Abnormality of the musculature	Sign or Symptom	phenotype
TCMBANKDI013927	Respiratory Tract Diseases	Abnormality of the respiratory system	Pathologic Function	phenotype
TCMBANKDI015485	Mental Disorders	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease
TCMBANKDI017581	-	-	Finding	phenotype
TCMBANKDI018635	Digestive System Diseases	Abnormality of the digestive system	Disease or Syndrome	disease
TCMBANKDI018680	Eye Diseases; Immune System Diseases; Endocrine System Diseases	Abnormality of the endocrine system	Disease or Syndrome	disease
TCMBANKDI018761	-	-	Diagnostic Procedure	phenotype
TCMBANKDI018836	-	-	Disease or Syndrome	disease
TCMBANKDI018930	Pathological Conditions, Signs and Symptoms; Musculoskeletal Diseases; Nervous System Diseases	Abnormality of limbs; Abnormality of the musculature	Finding	phenotype
TCMBANKDI019267	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the nervous system	Sign or Symptom	phenotype
TCMBANKDI022390	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI023464	Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI024149	-	-	Finding	phenotype
TCMBANKDI024895	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the musculature	Finding	phenotype
TCMBANKDI024935	Endocrine System Diseases	Abnormality of the endocrine system	Disease or Syndrome	phenotype
TCMBANKDI026020	Nutritional and Metabolic Diseases	Abnormality of metabolism/homeostasis	Finding	phenotype
TCMBANKDI026997	-	Abnormality of metabolism/homeostasis	Finding	phenotype
TCMBANKDI027318	-	Abnormality of the musculature	Finding	phenotype
TCMBANKDI027406	-	Abnormality of the nervous system; Abnormality of the musculature	Finding	phenotype
TCMBANKDI027669	-	-	Finding	phenotype
TCMBANKDI028701	Pathological Conditions, Signs and Symptoms	Growth abnormality	Finding	phenotype